Clinical Testing News and Research

RSS

Mild exercises for the bed-bound patients helps to combat muscle wasting

Critical care experts at Johns Hopkins are reporting initial success in boosting recovery and combating muscle wasting among critically ill, mostly bed-bound patients using any one of a trio of mild physical therapy exercises during their stays in the intensive care unit (ICU).

22 Sep 2009

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

21 Sep 2009

Bioniche announces fiscal 2009 year-end results

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

19 Sep 2009

BioCision's partnership with Therapak for distributing its products in clinical market

BioCision LLC, the CoolRack company, today announced that it has entered into an agreement with Therapak Corporation for the distribution of BioCision’s products into the clinical market. The deal marks BioCision’s first distribution agreement for the clinical market and expands its access to clinical settings across the United States and Europe.

16 Sep 2009

NIAID awards Sanaria an SBIR Grant for expediting its malaria vaccine manufacturing process

Sanaria Inc. has received additional support from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The award for two years is $1.99 million. Subject to satisfactory progress by Sanaria, continued funding for a third year will bring the total to nearly $3 million.

16 Sep 2009

KYTHERA initiates proof-of-concept trial of its ATX-104 light-activated facial contouring agent

KYTHERA Biopharmaceuticals, Inc. (KYTHERA) today announced that it has initiated a first-in-human, proof-of-concept study evaluating the safety, tolerability, persistence and histological effects of ATX-104, a light-activated facial contouring agent.

15 Sep 2009

FDA clearance for PRO-STIM bone graft substitute

Wright Medical Group, Inc., a global orthopaedic medical device company, today announced the 510K clearance of PRO-STIM™ Injectable Osteoinductive Bone Graft Substitute. PRO-STIM™ graft is a composite grafting material that is injected through a small needle, hardens, and is replaced by the patient’s new bone over time.

14 Sep 2009

CDI and VivoMedica launch pharmaceutical industry consortium

Cellular Dynamics International (CDI) and VivoMedica plc announce the launch of CARDIOTOX - a pharmaceutical industry consortium to validate a human cell model and analysis system for preclinical cardiotoxicity testing of pharmaceutical candidate compounds.

14 Sep 2009

NIH provides Inviragen second major grant to develop a dengue vaccine

Inviragen has received a $600,000 grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to partially support its continued efforts to develop a safe and effective dengue vaccine. The two-year grant will fund a collaborative effort led by Inviragen and involving scientists at the University of Wisconsin and Division of Vector-Borne Infectious Diseases at the Centers for Disease Control and Prevention (CDC). The supported work will include additional optimization of Inviragen’s vaccine to generate more potent immune responses.

10 Sep 2009

New study highlights the competitive nature of drug development

Marketing exclusivity periods for first-in-class drugs have fallen dramatically in recent decades -- from a median of 10.2 years in the 1970s to 2.5 years in the early part of this decade -- underscoring the competitive nature of drug development, a new study recently completed by the Tufts Center for the Study of Drug Development has found.

10 Sep 2009

Inspire Pharmaceuticals wins award for its denufosol tetrasodium program

Inspire Pharmaceuticals, Inc. announced today it received the North Carolina Health & Life Sciences Award in the category of “Breakthrough Research” for its denufosol tetrasodium program for cystic fibrosis (CF).

9 Sep 2009

Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12

NOXXON Pharma AG (NOXXON), clinical-stage developer of L-RNA based scaffolds (Spiegelmers®) that bind their targets conceptually similar to antibodies, announced today that the company was awarded a research grant from Germany’s Federal Ministry of Education and Research (BMBF) under the ministry’s small and medium enterprise innovation initiative (“KMU-Innovativ”).

3 Sep 2009

National Cancer Institute awards grant to Receptor Logic for breast cancer research

Receptor Logic, Inc. announced today receipt of a Phase I Small Business Technology Transfer (STTR) Grant from the National Cancer Institute. The grant, entitled “Therapeutic Effectiveness of T-Cell Receptor mimic (TCRm™) Antibodies in Breast Cancer Treatment” will accelerate Investigational New Drug Application enabling studies surrounding lead candidate TCRm antibodies.

3 Sep 2009

Preliminary lab results of SHBAN hand sanitizer solution announced

BioTech Medics, Inc. (PINKSHEETS: BMCS) announces that it has received preliminary independent clinical testing of its patented SHBAN™ Hand Sanitizer Solution to demonstrate it kills the H1N1 (Swine) Influenza A virus.

3 Sep 2009

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Tioga Pharmaceuticals, Inc. and Ono Pharmaceutical Co, Ltd. Osaka, Japan today announced an exclusive license agreement under which Ono has licensed rights to develop and commercialize asimadoline in Japan, South Korea and Taiwan. Tioga retains all other rights to asimadoline.

2 Sep 2009

Endosense raises USD 36 million in Series B financing

Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced that it has received USD 36 million in Series B financing. Edmond de Rothschild Investment Partners (EdRIP) led the round, with additional participation from Neomed, Gimv, VI Partners (VI), Sectoral Asset Management, Ysios Capital Partners and Initiative Capital Romandie.

1 Sep 2009

MultiGEN Diagnostics launches new technology for clinical testing in molecular diagnostics

San Diego-based MultiGEN Diagnostics Inc. has launched a novel multi-target DNA sequencing technology (MultiGEN) for a wide range of clinical testing in molecular diagnostics.

1 Sep 2009

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company engaged in the development of high-value human therapeutics, today announced that study results demonstrated that arimoclomol exhibited both statistically significant neuroprotective and neuroregenerative effects in brain cells of animals induced with stroke, offering important insights into this drug candidate’s mechanism of action.

25 Aug 2009

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Physicians at The Mount Sinai Medical Center were the first in the country to perform a non-surgical procedure using sutures to tie off a left atrial appendage (LAA), which is the source of blood clots leading to stroke in patients with atrial fibrillation (AFib). AFib is the most common sustained heart-rhythm disorder in the United States.

24 Aug 2009

First batch of cancer vaccine from Cancer Vaccine Collaborative goes into trial

The first batch of NY-ESO-1 recombinant protein produced in a facility supported entirely by non-profit entities has successfully cleared regulatory review and has entered clinical testing. The clinical trials are part of the Cancer Vaccine Collaborative, a joint program of the Cancer Research Institute, Inc. (CRI) and the Ludwig Institute for Cancer Research Ltd. (LICR).

13 Aug 2009

Clinical Testing News and Research

Mild exercises for the bed-bound patients helps to combat muscle wasting

Bioniche Life Sciences' revenue increases by 21% for the fiscal year 2009

Bioniche announces fiscal 2009 year-end results

BioCision's partnership with Therapak for distributing its products in clinical market

NIAID awards Sanaria an SBIR Grant for expediting its malaria vaccine manufacturing process

KYTHERA initiates proof-of-concept trial of its ATX-104 light-activated facial contouring agent

FDA clearance for PRO-STIM bone graft substitute

CDI and VivoMedica launch pharmaceutical industry consortium

NIH provides Inviragen second major grant to develop a dengue vaccine

New study highlights the competitive nature of drug development

Inspire Pharmaceuticals wins award for its denufosol tetrasodium program

Germany’s BMBF awards NOXXON grant for developing Spiegelmer NOX-A12

National Cancer Institute awards grant to Receptor Logic for breast cancer research

Preliminary lab results of SHBAN hand sanitizer solution announced

Ono Pharmaceutical secures exclusive rights to develop and commercialize asimadoline in Japan

Endosense raises USD 36 million in Series B financing

MultiGEN Diagnostics launches new technology for clinical testing in molecular diagnostics

Cytrx’s study offers a better perception of arimoclomol's mechanism of action in induced animal stroke

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

First batch of cancer vaccine from Cancer Vaccine Collaborative goes into trial

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News